On January 26, 2017, venBio Select Advisor LLC announced that it has released a presentation titled: ‘The Case for Change at Immunomedics, Inc.’ venBio Select stated that this presentation can be found at: http://www.okapivote.com/immunomedics. In this presentation, venBio Select stated that it highlights the Company’s decades-long value destruction and underperformance and discusses how the Board of Directors and management have failed to advance the best interests of stockholders, especially due to the Company’s failure to form a strategic partnership to bring to market the Company’s promising Triple Negative Breast Cancer drug, IMMU-132.